Eevia Health Plc (publ) (”Eevia Health”, “Eevia” or “the Company”) concludes a transformative 2023, marked by a sharp decline in net sales during H2-23, mainly stemming from the shift away from heavy reliance on a single customer toward a more diversified customer base. Nonetheless, Eevia has demonstrated proof of efficiency, both in terms of production as well as the overall cost structure, underscored by the full year gross margin of 58% and a positive EBITDA result of EUR 0.8m. Based on current estimates and an applied EV/S multiple of 1.2x, a potential present value per share of SEK 2.0 (2.4) is derived in a Base scenario.

Link to the analysis